AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorArsenal Biosciences, Inc.
About this trial
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Eligibility criteria
Qualifiers
At least 18 years of age at time of signing informed consent form.
Prior prostate cancer treatment with at least 1 novel androgen receptor pathway inhibitor (ARPI) therapy.
Measurable disease by RECIST 1.1 criteria, or evaluable disease via measurable PSA (≥ 1 ng/mL) per PCWG3 criteria.
Adequate organ functions.
Disqualifiers
Any prior systemic therapy for CRPC within 14 days prior to scheduled protocol required leukapheresis.
Central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression.
Unwillingness to participate in an extended safety monitoring period.
Trial design
Treatments tested in this trial
- AB-3028
Treatment groups
190 Participants
are divided into 1 treatment groupLocations
9California
City of Hope91010, Duarte United States
USC Norris Comprehensive Cancer Center90033, Los Angeles United States
University of California, San Francisco94143, San Francisco United States
Colorado
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)80045, Aurora United States
Sponsors and collaborators
Arsenal Biosciences, Inc.
Lead sponsor
Source ClinicalTrials.gov